Boston, MA 05/12/2014 (wallstreetpr) – TESARO Inc (NASDAQ:TSRO) said that its researched-drug satisfied the main goal in a “delayed-stage Phase 3 trial”. Its experimental drug was developed for the impediment of chemotherapy-induced nausea and vomiting (CINV). It is undeniably excellent news for the cancer patients who bear the pain of chemotherapy regularly. The company developed this drug to relieve the patients from the continuous side effects of nausea and vomiting. As soon as the news was revealed, the company’s shares leaped to $27.50 in premarket trading, which is nearly 15% increase.
Rolapitant
The oncology-specialized biopharmaceutical company, announced affirmative top line report from the final third phase trial of rolapitant. The latter is a tentative neurokinin-1 (NK-1) receptor antagonist in the progress of the prevention of CINV. The trial enrolled patients who were receiving cisplatin-based, highly emetogenic chemotherapy (HEC). The rolapitant successfully attained statistical importance over the standard therapy for the entire primary as well as the secondary endpoints.
The company’s delight
The President of TESARO Inc (NASDAQ:TSRO), Mary Lynne Hedley, Ph.D, stated that the results demonstrate a differentiated profile for rolapitant, according to the company’s viewpoint. The president expressed the company’s enthusiasm about the potential for this product. The profile of this product candidate may include a comprehensive half life, single-dose oral, convenient and intravenous formulations. Tesaro is very pleased with such data. In addition, the biopharmaceutical company is also looking ahead to demonstrating the details of the results of the trial.
TESARO Inc (NASDAQ:TSRO) will be presenting detailed results alongside the report of the company’s former trials, conducted before Phase 3 trials at the nearing American Society of Clinical Oncology (ASCO) annual meeting.
The results
The Phase 3 of rolapitant was a multi-centre, double blind, randomized, active-controlled, global study, which enrolled 532 cancer affected receiving cisplatin-based chemotherapy regimens. The dosage of such regimens is equal to or more than 60 mg/m2. Tolerability and safety data for patients receiving rolapitant were same as the results for the ones receiving control. In addition, the data was also consistent with the earlier clinical studies.
